Inaktiver Wert

Andere Sprachen Foamix Pharmaceuticals Ltd. Nasdaq

Aktien

A12BKW

IL0011334385

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	09.05.
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update	09.05.
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	06.05.
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	06.05.
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	06.05.
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	01.05.
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	19.03.
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	29.02.
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	29.02.
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	27.02.
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	21.02.
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	10.01.
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	10.01.
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	03.01.
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	03.01.
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	13.11.
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Foamix Pharmaceuticals Ltd. Nasdaq

Aktien

A12BKW

IL0011334385

Andere Sprachen

Filter